Gainers

• iSpecimen (NASDAQ:ISPC) stock moved upwards by 16.1% to $0.92 during Thursday's after-market session. The company's market cap stands at $2.2 million.
• CareDx (NASDAQ:CDNA) stock rose 15.0% to $82.25. The company's market cap stands at $3.7 billion. As per the press release, Q3 earnings came out today.
• LeonaBio (NASDAQ:LONA) stock rose 11.13% to $5.46. The market value of their outstanding shares is at $46.7 million.
• Bio Green Med Solution (NASDAQ:BGMS) shares increased by 6.31% to $0.88. The market value of their outstanding shares is at $6.0 million.
• Scienture Holdings (NASDAQ:SCNX) shares moved upwards by 6.01% to $3.7. The market value of their outstanding shares is at $5.5 million.
• Exicure (NASDAQ:XCUR) shares rose 5.83% to $0.99. The company's market cap stands at $6.6 million.

Losers

• Alphatec Holdings (NASDAQ:ATEC) shares fell 31.8% to $7.76 during Thursday's after-market session. The market value of their outstanding shares is at $1.7 billion. As per the news, the Q3 earnings report came out today.
• GlucoTrack (NASDAQ:GCTK) stock declined by 30.59% to $0.96. The company's market cap stands at $2.4 million.
• Lunai Bioworks (NASDAQ:LNAI) shares decreased by 25.73% to $0.12. The market value of their outstanding shares is at $1.1 million.
• Stryker (NYSE:SYK) stock decreased by 12.11% to $274.0. The company's market cap stands at $116.4 billion. As per the press release, Q3 earnings came out today.
• Illumina (NASDAQ:ILMN) shares decreased by 12.09% to $255.0. The market value of their outstanding shares is at $44.1 billion. The company's, Q3 earnings came out today.
• Alignment Healthcare (NASDAQ:ALHC) shares fell 9.93% to $7.26. The market value of their outstanding shares is at $1.6 billion. As per the news, the Q3 earnings report came out today. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.